A fluorescein derivative and its preparation method and application
By developing a new fluorescein derivative, using different connecting arms L to connect trimethyllock quinone and fluorescent chromophore, and combining spirocyclic lactone structure, the problems of poor selectivity and low sensitivity of existing fluorescent probes are solved. High selectivity and high sensitivity detection of quinone oxidoreductase is achieved to support early cancer diagnosis.
Patent Information
- Application Number
- CN202211613528.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-12-15
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2042-12-15
AI Technical Summary
The existing fluorescent probes used for quinone oxidoreductase detection have problems such as poor selectivity, low detection sensitivity, and long response time, making it difficult to achieve effective support for early cancer diagnosis.
A novel fluorescein derivative was developed that connects trimethyllock quinone to fluorescent chromophores through different linking arms L, promoting photoelectron transfer, combining spirocyclic lactone structures to reduce autofluorescence and reactive oxygen generation ability to improve detection sensitivity.
High selectivity and high sensitivity detection of quinone oxidoreductase is achieved, visible fluorescence changes can occur within 1 minute and significant fluorescence differences can occur within 5 minutes, and has high biological application prospects.
Smart Images

Figure CN115960115B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical technology, and in particular to a fluorescein derivative and a preparation method and application thereof. Background Art
[0002] Cancer is a malignant disease that threatens human health. It is the second largest disease in the world and one of the leading causes of death in humans. Currently, the main treatment for cancer is radical surgical removal of cancer cells. The main obstacle to cancer treatment now is the difficulty in early diagnosis of cancer, which leads to missing the best time to treat cancer. Early detection of cancer biomarkers and research on innovative therapies are of great significance for the effective control and treatment of cancer. Quinone oxidoreductase (NQO1) is differentially expressed in normal cells and tumor cells, and its content is excessively elevated in many cancer cells. Therefore, quinone oxidoreductase can be used as a biomarker for selective cancer treatment and precise cancer detection.
[0003] In recent years, a large number of fluorescent probes have been developed for the detection and quantitative analysis of quinone oxidoreductase in tumors. However, due to the complexity of the environment in biological tissues, the fluorescent signal will inevitably be interfered by the background fluorescence of the biological tissue itself. During long-term biological imaging, fluorescent probes are affected by the aggregation-induced quenching (ACQ) effect, resulting in low detection sensitivity and non-specific detection during the detection process. Therefore, the development of fluorescent probes with rapid response, high selectivity and high sensitivity for detecting quinone oxidoreductase is of great significance for the early diagnosis of cancer diseases, as well as a comprehensive understanding of the pathogenesis of cancer and the development of related drugs. Summary of the invention
[0004] In view of the problems that existing fluorescent probes for quinone oxidoreductase detection have poor selectivity, low detection sensitivity, long response time, etc., the present invention provides a fluorescein derivative and a preparation method and application thereof.
[0005] In order to solve the above technical problems, the technical solution provided by the present invention is:
[0006] A fluorescein derivative, the structure of which is shown in Formula I, Formula II or Formula III:
[0007]
[0008] Among them, X, X 0 are respectively selected from H, F, Cl, Br or I;
[0009] R, R 1 Selected from H, L 1 , L 2 , L 3 , L4 , L 5 , L 6 or L 7 ;
[0010]
[0011] R 2 Selected from (CH 2 ) n+1 or (CH 2 ) n+1 O(CH 2 ) n+1 ; R 3 Selected from H or CH 3 ;
[0012] R 4 Selected from (CH 2 ) n ; n is an integer from 0 to 8.
[0013] It should be noted that, for the sake of simplicity, the structural formula of the above-mentioned fluorescein derivative is simplified to the following structure:
[0014]
[0015] L stands for O,
[0016] Compared with the prior art, the present invention provides a fluorescein derivative with a novel structure, in which trimethyl lock-quinone is connected to a fluorescent chromophore through different connecting arms L. This connection method effectively promotes the photoinduced electron transfer between trimethyl lock-quinone and the fluorescent chromophore. The spirolactone structure can minimize the autofluorescence and reactive oxygen generation ability of the fluorescein derivative, thereby effectively reducing background fluorescence, greatly improving the sensitivity of fluorescence detection, and realizing high-quality fluorescence imaging, which has broad biological application prospects.
[0017] Preferably, the structure of the fluorescein derivative is as follows:
[0018]
[0019] The present invention also provides a method for preparing the above-mentioned fluorescein derivative, comprising the following steps:
[0020] Step a, dissolving compound 1 and urotropine in an organic solvent a, reacting at 70° C.-160° C. for 20 h-40 h, cooling, adjusting the pH of the reaction solution to 2-4, filtering, washing, and drying to obtain compound 2;
[0021]
[0022] Step b, under an inert atmosphere, dissolving compound 2 in an organic solvent b, adding intermediate a and piperidine, reacting at 90° C.-180° C. for 30 h-40 h, cooling, and purifying to obtain compound 3;
[0023]
[0024] Wherein, the intermediate a is selected from the following compounds:
[0025]
[0026] Step c, under an inert atmosphere, compound 4, intermediate Q, 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate and N,N-diisopropylethylamine are added to an organic solvent c, reacted at 0°C-5°C for 5min-30min, heated to 10°C-30°C for 18h-60h, cooled, and purified to obtain compound 5;
[0027]
[0028] Among them, when the intermediate Q is R 3 -NH-R 2 -COOH, compound 5 is:
[0029]
[0030] When the intermediate Q is NH 2 (C 6 H 4 )R 4 When COOH, compound 5 is:
[0031]
[0032] Step d, under an inert atmosphere, compound 3, compound 4, 4-dimethylaminopyridine and dicyclohexylcarbodiimide are added to an organic solvent d, reacted at 0°C-5°C for 0.1h-2.5h, heated to 50°C-150°C for 1h-3.5h, cooled to 10°C-30°C, and continued to react for 18h-48h to obtain a fluorescein derivative represented by formula I;
[0033] Under an inert atmosphere, compound 3, compound 5, 4-dimethylaminopyridine and dicyclohexylcarbodiimide are added to an organic solvent d, reacted at 0°C-5°C for 0.1h-2.5h, heated to 50°C-150°C for 1h-3.5h, cooled to 10°C-30°C, and continued to react for 18h-48h to obtain a fluorescein derivative represented by formula II or formula III.
[0034] The fluorescein derivative provided by the present invention is a type of fluorescein derivative that specifically recognizes quinone oxidoreductase, which is obtained by introducing an aldehyde group through a Duff reaction on the basis of 2,7-dichlorofluorescein, then obtaining a dye parent structure through a Knoevenagel-condensation reaction, and finally linking different linking arms L. The raw materials of the synthesis method are easily available, the synthesis route is simple, the reaction conditions are mild, and the product yield is high.
[0035] Preferably, in step a, the molar ratio of compound 1 to urotropine is 1:(2-6).
[0036] Preferably, in step a, the molar ratio of compound 1 to organic solvent a is 1:(50-300).
[0037] Preferably, in step a, the organic solvent a is at least one of trifluoroacetic acid, dichloromethane, chloroform, ethanol, acetonitrile, ethyl acetate, toluene, xylene or o-dichlorobenzene.
[0038] Furthermore, in step a, the pH of the reaction solution is adjusted to 2-4 using hydrochloric acid solution, acetic acid solution or sulfuric acid solution. Preferably, the concentration of the acid solution is 1.0M-3.0M.
[0039] Preferably, in step b, the molar ratio of compound 2 to intermediate a is 1:(1-8).
[0040] Preferably, in step b, the molar ratio of compound 2 to piperidine is 1:(2-8).
[0041] Preferably, in step b, the molar ratio of the compound 2 to the organic solvent b is 1:(100-600).
[0042] Preferably, in step b, the organic solvent b is at least one of methanol, ethanol, acetonitrile, toluene, xylene, o-dichlorobenzene or N,N-dimethylformamide.
[0043] Furthermore, in step b, the specific steps of purification are: distilling the cooled reaction solution under reduced pressure to remove the solvent, adding an organic solvent to dissolve the reaction product, then adding it to cold ether, filtering it with suction, and purifying it by column chromatography to obtain compound 3.
[0044] In combination with the above, the organic solvent is methanol, ethanol or N,N-dimethylformamide, and the molar ratio of the organic solvent to the compound 2 is 1:(40-60); the temperature of the cold ether is 0°C-6°C, and the molar ratio of the compound 2 to the cold ether is 1:(2000-4000).
[0045] In combination with the above, the column chromatography is a chromatography column using silica gel (300-400 mesh) as a filler, and elution is performed using dichloromethane and methanol in a volume ratio of 50:1 as an eluent, and the target component is collected, concentrated, and dried to obtain compound 3.
[0046] Preferably, in step c, the molar ratio of compound 4, intermediate Q, 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate and N,N-diisopropylethylamine is 1:(1-2):(1-6):(15-30).
[0047] Preferably, in step c, the molar ratio of compound 4 to organic solvent c is 1:(300-1500).
[0048] Preferably, in step c, the organic solvent c is at least one of dichloromethane, acetonitrile, toluene, xylene, o-dichlorobenzene or N,N-dimethylformamide.
[0049] Furthermore, in step c, the purification step is: concentrating the reaction solution after the reaction is completed, drying it, and then purifying it by column chromatography to obtain compound 5.
[0050] In combination with the above, column chromatography was performed using 300-400 mesh silica gel as filler and petroleum ether and ethyl acetate in a volume ratio of 5:1 as eluent. The target components were collected, concentrated, and dried to obtain compound 5.
[0051] Preferably, in step d, the molar ratio of compound 3, compound 4, 4-dimethylaminopyridine and dicyclohexylcarbodiimide is 1:(10-25):(1-8):(20-30).
[0052] Preferably, in step d, the molar ratio of compound 3, compound 5, 4-dimethylaminopyridine and dicyclohexylcarbodiimide is 1:(15-30):(1-12):(20-30).
[0053] Preferably, in step d, the molar ratio of the compound 3 to the organic solvent d is 1:(1000-2500).
[0054] Preferably, in step d, the organic solvent d is at least one of dichloromethane, acetonitrile, toluene, xylene, o-dichlorobenzene or N,N-dimethylformamide.
[0055] Furthermore, in step d, a purification step is also included after the reaction is completed. The purification step specifically comprises: concentrating the reaction solution after the reaction is completed, drying it, and then performing column chromatography purification to obtain a fluorescein derivative.
[0056] In combination with the above, column chromatography uses 300-400 mesh silica gel as filler, and dichloromethane and ethanol in a volume ratio of 100:1 as eluent, collects the target component, concentrates, and dries to obtain the fluorescein derivative.
[0057] The preferred molar ratio of the reaction raw materials, solvent, reaction temperature and reaction time are conducive to fully carrying out the reaction, improving the conversion rate of the raw materials, and further improving the yield of the product.
[0058] The inert atmosphere in the present invention can be provided by conventional inert gases in the art, such as nitrogen, argon or carbon dioxide.
[0059] The present invention also provides a fluorescent probe, comprising the above-mentioned fluorescein derivative.
[0060] The present invention also provides application of the above-mentioned fluorescein derivative in detection of quinone oxidoreductase.
[0061] The present invention also provides application of the fluorescent probe in detecting quinone oxidoreductase.
[0062] The fluorescein derivative provided by the present invention is prepared into a fluorescent probe, which can realize the specific recognition of quinone oxidoreductase, has high sensitivity, and has almost no toxic side effects on normal cells and tissues. It can be used as an excellent fluorescent probe for qualitative and quantitative detection of quinone oxidoreductase and biological research, tumor cell fluorescence detection, and differentiation of different types of tumor cells, and has broad biological application prospects.
[0063] The fluorescein derivative provided by the present invention is suitable for the detection of quinone oxidoreductase, can show visible fluorescence changes within 1 minute, and can show significant fluorescence differences within 5 minutes, and has high selectivity, has no obvious fluorescence response to common interferents such as amino acids, metal ions, active oxygen, active nitrogen, reduced thiols and some other oxidoreductases, and has a detection limit of about 20 ng / mL. It has almost no toxic side effects on normal cells and tissues, has higher safety, and is expected to be applied to the detection of quinone oxidoreductase in real biological tissues, realizing real-time visual detection of quinone oxidoreductase, and has broad application prospects.
[0064] The present invention also provides the use of the above-mentioned fluorescein derivative as a photosensitizer for photodynamic therapy.
[0065] The fluorescein derivatives of the present invention that specifically recognize quinone oxidoreductase are based on the fluorescent chromophore obtained by modifying fluorescein to link the substrate trimethyl lockquinone of quinone oxidoreductase through different linker arms L to obtain a fluorescein derivative of a novel structure, which can specifically recognize quinone oxidoreductase. Among them, trimethyl lockquinone hinders S through the photoinduced electron transfer (PET) process. 1 To S 0The fluorescence emission process of the probe is as follows: at this time, the fluorescein derivative has no fluorescence signal and singlet oxygen generation ability; under the catalysis of quinone oxidoreductase, the reduced coenzyme II reduces the lock-quinone part of the probe to hydroquinone, and the hydroxyl group on the hydroquinone nucleophilically attacks the carbonyl group of the quinone propionic acid part to undergo a lactonization reaction. The obtained product can produce a strong fluorescence signal and has excellent singlet oxygen generation ability, so that it can not only perform qualitative and quantitative detection of quinone oxidoreductase, but also has tumor targeting and good singlet oxygen generation ability, and has almost no toxic side effects on normal cells and tissues. It can be used as an excellent fluorescent probe for qualitative and quantitative and biological research on quinone oxidoreductase, tumor cell detection imaging, differentiation of different types of tumor cells, tumor targeting and photodynamic therapy, etc.; in addition, because of its microsecond long-life fluorescence (the fluorescence lifetime at 620nm can reach 24μs), compared with short-life traditional fluorescent probes, it can eliminate biological background fluorescence interference and achieve high-quality fluorescence imaging, and has broad biological application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0066] Figure 1 Fluorescence imaging images of the fluorescein derivative DCF-ZZH prepared in Example 3 co-incubated with tumor A549 cells for different time periods, where (a) 5 min, (b) 10 min, (c) 20 min, and (d) 40 min;
[0067] Figure 2 The fluorescence imaging images of the fluorescein derivative DCF-ZZH prepared in Example 3 on tumor cells with different quinone oxidoreductase expression levels, including: (a) fluorescence imaging image of DCF-ZZH on tumor OVCAR-3 cells, (b) fluorescence imaging image of DCF-ZZH on tumor A549 cells, (c) fluorescence imaging image of DCF-ZZH on tumor A549 cells without pre-incubation with dicoumarol in an inhibition test; (d) fluorescence imaging image of DCF-ZZH on tumor A549 cells pre-incubated with dicoumarol in an inhibition test. DETAILED DESCRIPTION
[0068] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.
[0069] In order to better illustrate the present invention, further examples are given below.
[0070] Example 1
[0071] Preparation of a class of fluorescein derivatives DCF-ZZH-0 that specifically recognize quinone oxidoreductase:
[0072] (1) Preparation of intermediate III
[0073] At room temperature, compound II (1.0 g, 2.5 mmol) and urotropine (1.746 g, 12.5 mmol) were dissolved in a round-bottom flask containing 30 mL of trifluoroacetic acid, heated to 90 ° C and refluxed for 36 h, the mixture became dark brown and viscous, and the reaction product was cooled to room temperature (25 ° C), added to a beaker filled with a large amount of ice cubes, and 2M hydrochloric acid aqueous solution was added to adjust the pH to 4, and stirring was continued for 4 h until solid precipitated. The filter cake was obtained by suction filtration in a Buchner funnel, washed three times with distilled water and dried to obtain an orange-red solid compound III, which was directly subjected to the next step of reaction without purification.
[0074] (2) Preparation of intermediate DCF-LHF-0
[0075] Under nitrogen protection, compound III (0.456 g, 1 mmol) was dissolved in 15 mL of dry anhydrous ethanol, 2-acetylthiophene (0.504 g, 4 mmol) intermediate was added and stirred. After the mixture was stirred evenly, piperidine (0.4 mL) was added and heated to 100 ° C. and refluxed for 32 h under nitrogen protection. After the reaction was completed, the temperature of the reactant dropped to room temperature (25 ° C.), and the solvent was removed by reduced pressure distillation. Methanol (2 mL) was added to dissolve the reaction product, and the solid was precipitated in ether (300 mL) at 0 ° C. The filter cake was obtained by suction filtration in a Buchner funnel, washed three times with distilled water, and then dried to obtain a crude product. Silica gel (300-400 mesh) was used as column chromatography filler, and dichloromethane and methanol system were used as mobile phases for elution. The volume ratio of dichloromethane to methanol was 50:1. The dark red part was collected, concentrated, and dried to obtain compound DCF-LHF-0 (0.159 g, yield was 23.69%, purity was 98%).
[0076] HRMS (ESI) m / z calcd.for C 34 H 17 Cl 2 O 7 S 2 - (MH) - 670.9798, found 670.9794.
[0077] (3) Preparation of intermediate VI
[0078] Under nitrogen protection, compound V (0.05 g, 0.2 mmol), 4-aminophenylacetic acid (0.03 g, 0.2 mmol), 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (0.128 g, 0.34 mmol) and N,N-diisopropylethylamine (0.516 g, 4 mmol) were added to 10 mL of anhydrous N,N-dimethylformamide and stirred. After reacting at 0°C for 10 min, the mixture was heated to room temperature (25°C) and reacted for 24 h. The crude product was dried to obtain a crude product. Silica gel (300-400 mesh) was used as column chromatography filler. A petroleum ether and ethyl acetate system with a volume ratio of 5:1 was used as the mobile phase for elution. The yellow portion was collected, concentrated and dried to obtain compound VI (0.045 g, yield was 58.75%, purity was 98%).
[0079] HRMS (ESI) m / z calcd.for C 22 H 24 NO 5 - (MH) - 382.1659, found 382.1655.
[0080] (4) Preparation of compound DCF-ZZH-0
[0081] Under nitrogen protection, compound DCF-LHF-0 (0.1 g, 0.15 mmol) and compound Ⅵ (1.027 g, 2.68 mmol) were dissolved in 15 mL of dry dichloromethane, and then 4-dimethylaminopyridine (0.0195 g, 0.16 mmol) and dicyclohexylcarbodiimide (0.70 g, 3.4 mmol) were added thereto. The mixture was stirred at 0°C for 0.2 h under a nitrogen atmosphere. After the reaction, the temperature was raised to 60°C for 2 h, and the temperature was lowered to room temperature (25°C) for 36 h. After the reaction was completed, the solvent was removed by distillation under reduced pressure to obtain a crude product. Silica gel (300-400 mesh) was used as a column chromatography filler, and a dichloromethane and ethanol system with a volume ratio of 100:1 was used as the mobile phase for elution. The dark brown portion was collected, concentrated, and dried to obtain the fluorescein derivative DCF-ZZH-0 (0.025 g, yield was 16.13%, purity was 98%).
[0082] 1 H NMR (400 MHz, DMSO-d 6)δ8.20(1H),8.02(2H),7.73(2H),7.71(2H),7.68(1H),7.66(1H),7.63(2H),7.33(1H),7.13(2H) ,6.93(1H),6.87(2H),6.81(2H),6.48(2H),3.31(2H),2.82(2H),2.06(3H),1.87(6H),1.35(6H).
[0083] HRMS (ESI) m / z calcd.for C 56 H 41 Cl 2 NO 11 S 2 Na + (M+Na) + 1060.1391, found 1060.1388.
[0084]
[0085] Example 2
[0086] Preparation of a class of fluorescein derivatives DCF-ZZH-1 that specifically recognize quinone oxidoreductase:
[0087] (1) Preparation of intermediate III
[0088] At room temperature, compound II (1.0 g, 2.5 mmol) and urotropine (1.746 g, 12.5 mmol) were dissolved in a round-bottom flask containing 30 mL of trifluoroacetic acid. The mixture was heated to 90°C and refluxed for 36 h. The mixture became dark brown and viscous. After the reaction product was cooled to room temperature (25°C), it was added to a beaker containing a large amount of ice cubes, and a 2M hydrochloric acid aqueous solution was added to adjust the pH to 4. Stirring was continued for 4 h until solids precipitated. The filter cake was obtained by suction filtration in a Buchner funnel, washed three times with distilled water, and dried to obtain an orange-red solid compound III, which was directly used for the next step without purification.
[0089] (2) Preparation of intermediate DCF-LHF-1
[0090] Under nitrogen protection, compound III (0.456 g, 1 mmol) was dissolved in 15 mL of dry anhydrous ethanol, 1-naphthyl acetonide (0.680 g, 4 mmol) intermediate was added and stirred. After the mixture was stirred evenly, piperidine (0.4 mL) was added and heated to 100 ° C. and refluxed for 32 h under nitrogen protection. After the reaction was completed, the temperature of the reactant dropped to room temperature (25 ° C.), and the solvent was removed by reduced pressure distillation. Methanol (2 mL) was added to dissolve the reaction product, and the solid was precipitated in ether (300 mL) at 0 ° C. The filter cake was obtained by suction filtration in a Buchner funnel, washed three times with distilled water, and then dried to obtain a crude product. Silica gel (300-400 mesh) was used as column chromatography filler, and a dichloromethane and methanol system with a volume ratio of 50:1 was used as the mobile phase for elution. The dark red part was collected, concentrated, and dried to obtain compound DCF-LHF-1 (0.137 g, yield was 18.03%, purity was 98%).
[0091] HRMS (ESI) m / z calcd.for C 46 H 25 Cl 2 O 7 - (MH) - 759.0982, found 759.0976.
[0092] (3) Preparation of intermediate VI
[0093] Under nitrogen protection, compound V (0.05 g, 0.2 mmol), 4-aminophenylacetic acid (0.03 g, 0.2 mmol), 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (0.128 g, 0.4 mmol) and N,N-diisopropylethylamine (0.516 g, 4 mmol) were added to 10 mL of anhydrous N,N-dimethylformamide and stirred. After reacting at 0°C for 10 min, the mixture was heated to room temperature (25°C) and reacted for 24 h. The crude product was dried to obtain a crude product. Silica gel (300-400 mesh) was used as column chromatography filler. A petroleum ether and ethyl acetate system with a volume ratio of 5:1 was used as the mobile phase for elution. The yellow portion was collected, concentrated and dried to obtain compound VI (0.045 g, yield was 58.75%, purity was 98%).
[0094] HRMS (ESI) m / z calcd.for C 22 H 24 NO 5 - (MH) - 382.1659, found 382.1655.
[0095] (4) Preparation of compound DCF-ZZH-1
[0096] Under nitrogen protection, compound DCF-LHF-1 (0.1 g, 0.13 mmol) and compound Ⅵ (1.072 g, 2.8 mmol) were dissolved in 15 mL of dry dichloromethane, and then 4-dimethylaminopyridine (0.0195 g, 0.16 mmol) and dicyclohexylcarbodiimide (0.70 g, 3.4 mmol) were added thereto. The mixture was stirred at 0°C for 0.2 h under a nitrogen atmosphere. After the reaction, the temperature was raised to 60°C for 2 h, and the temperature was lowered to room temperature (25°C) for 36 h. After the reaction was completed, the solvent was removed by distillation under reduced pressure to obtain a crude product. Silica gel (300-400 mesh) was used as a column chromatography filler, and a dichloromethane and ethanol system with a volume ratio of 100:1 was used as the mobile phase for elution. The dark brown portion was collected, concentrated, and dried to obtain the fluorescein derivative DCF-ZZH-1 (0.023 g, yield was 13.69%, purity was 98%).
[0097] 1 H NMR (400 MHz, DMSO-d 6 )δ8.58(2H),8.20(1H),8.08(2H),8.03(2H),7.94(2H),7.73(2H),7.68(1H),7.66(1H),7.33(2H),7.30(1H),7.27(2H) ,7.18(2H),7.13(2H),6.90(1H),6.87(2H),6.82(2H),6.48(2H),3.31(2H),2.82(2H),2.06(3H),1.88(6H),1.36(6H).
[0098] HRMS (ESI) m / z calcd.for C 68 H 49 Cl 2 NO 11 Na + (M+Na) + 1148.2575, found 1148.2569.
[0099]
[0100] Example 3
[0101] Preparation of a class of fluorescein derivatives DCF-ZZH that specifically recognize quinone oxidoreductase:
[0102] (1) Preparation of intermediate III
[0103] At room temperature, compound II (1.0 g, 2.5 mmol) and urotropine (1.746 g, 12.5 mmol) were dissolved in a round-bottom flask containing 30 mL of trifluoroacetic acid, heated to 90 ° C and refluxed for 36 h, the mixture became dark brown and viscous, and the reaction product was cooled to room temperature (25 ° C) and added to a beaker filled with a large amount of ice cubes, and 2M hydrochloric acid aqueous solution was added to adjust the pH to 4, and stirring was continued for 4 h until solid precipitated. The filter cake was obtained by suction filtration in a Buchner funnel, washed three times with distilled water and dried to obtain an orange-red solid compound III, which was directly subjected to the next step of reaction without purification.
[0104] (2) Preparation of intermediate DCF-LHF
[0105] Under nitrogen protection, compound III (0.456 g, 1 mmol) was dissolved in 15 mL of dry anhydrous ethanol, and 2-(2,6-dimethyl-4H-pyran-4-ylidene)malononitrile (0.688 g, 4 mmol) intermediate was added and stirred. After the mixture was stirred evenly, piperidine (0.4 mL) was added and heated to 100 ° C and refluxed for 32 h under nitrogen protection. After the reaction was completed, the temperature of the reactant dropped to room temperature (25 ° C) and the solvent was removed by reduced pressure distillation. A small amount of methanol (2 mL) was added to dissolve the reaction product, and a solid was precipitated in ether (300 mL) at 0°C. The filter cake was obtained by suction filtration through a Buchner funnel, washed three times with distilled water and dried. Silica gel (300-400 mesh) was used as column chromatography filler, and a dichloromethane and methanol system with a volume ratio of 50:1 was used as the mobile phase for elution. The dark red portion was collected, concentrated, and dried to obtain compound DCF-LHF (0.105 g, yield was 13.74%, purity was 98%).
[0106] HRMS (ESI) m / z calcd.for C 42 H 21 Cl 2 N 4 O 7 - (MH) - 763.0792, found 763.0787.
[0107] (3) Preparation of compound DCF-ZZH
[0108] Under nitrogen protection, compound DCF-LHF (0.1 g, 0.13 mmol) and compound V (0.7 g, 2.8 mmol) were dissolved in 15 mL of dry dichloromethane, and then 4-dimethylaminopyridine (0.02 g, 0.16 mmol) and dicyclohexylcarbodiimide (0.7 g, 3.4 mmol) were added thereto. The mixture was stirred at 0°C for 0.2 h under a nitrogen atmosphere. After the reaction, the temperature was raised to 60°C for 2 h, and the temperature was lowered to room temperature (25°C) for 36 h. After the reaction was completed, the solvent was removed by distillation under reduced pressure to obtain a crude product. Silica gel (300-400 mesh) was used as column chromatography filler, and a dichloromethane and ethanol system with a volume ratio of 100:1 was used as the mobile phase for elution. The dark brown portion was collected, concentrated, and dried to obtain the fluorescein derivative DCF-ZZH (0.018 g, yield was 13.90%, purity 98%).
[0109] 1 H NMR (400 MHz, DMSO-d 6 )δ8.21(1H),8.01(2H),7.73(2H),7.66(1H),7.64(1H),7.33(1H),6.81(2H) ,6.62(2H),6.46(2H),2.80(2H),2.36(6H),2.06(3H),1.86(6H),1.36(6H).
[0110] HRMS (ESI) m / z calcd.for C 56 H 38 Cl 2 N 4 O 10 Na + (M+Na) + 1019.1857, found 1019.1852.
[0111]
[0112] In the above-mentioned Examples 1-3, other reaction conditions specified in the present invention, such as the ratio of reaction raw materials, solvent, reaction temperature and time, etc., as long as they are within the range specified in the specification of the present invention, can achieve effects substantially equivalent to those of Examples 1-3.
[0113] Embodiment 4-8
[0114] The synthesis of fluorescein derivatives 4-8 was performed by referring to the above method, and the specific process parameters can be obtained by those skilled in the art by routine adjustment according to Examples 1-3.
[0115]
[0116]
[0117]
[0118] The structural formula of the fluorescein derivative prepared above is as follows:
[0119]
[0120] Performance Testing
[0121] 1. Specificity detection
[0122] The specific recognition of quinone oxidoreductase by three fluorescein derivatives (DCF-ZZH-0, DCF-ZZH-1 and DCF-ZZH) prepared in Examples 1 to 3 of the present invention was studied.
[0123] Amino acids, ions, reactive oxygen, reactive nitrogen, reduced thiols and some oxidoreductases present in organisms may interfere with the detection of fluorescein derivatives. In order to explore whether fluorescein derivatives (DCF-ZZH-0, DCF-ZZH-1 and DCF-ZZH) have a specific response to quinone oxidoreductase, different biologically relevant analytes (all at a concentration of 100 μM) were detected under the same conditions: valine (Leu), alanine (Ala), arginine (Arg), glutamic acid (Glu), glycine (Gly), tyrosine (Tyr), histidine (His), K + 、Na + , Ca 2+ Mg 2+ , H 2 O 2 , NaClO, cysteine (Cys), dithiothreitol (DTT), glutathione (GSH), homocysteine (Hcy), ascorbic acid (AA), catalase (CAT) were tested, and the changes in fluorescence intensity after the reaction of these analytes and fluorescein derivatives (all at a concentration of 10 μM) were further monitored. A fluorescence spectrophotometer was used with an excitation wavelength of 550 nm and an emission wavelength receiving range of 580-660 nm.
[0124] The concentration of each interfering analyte was 100 μM, the concentration of bovine serum albumin (BSA) was 0.007%, and the concentration of reduced coenzyme II (NADPH) was 100 μM. The amino acids (Leu, Ala, Arg, Glu, Gly, Tyr, His), metal cations (K + , Na + , Ca 2+ ,Mg 2+ ), active oxygen (H2 O 2 , NaClO), reducing substances (Cys, DTT, GSH, Hcy, AA, CAT) and fluorescein derivatives (DCF-ZZH-0, DCF-ZZH-1 and DCF-ZZH) were reacted at 37°C for 12 min and then the changes in fluorescence intensity were detected.
[0125] At the same time, a test solution with a quinone oxidoreductase concentration of 10 μM, a bovine serum albumin (BSA) mass concentration of 0.007% and a reduced coenzyme II (NADPH) concentration of 100 μM was prepared using 10 mM PBS (pH = 7.4) buffer. The test solution was tested by reacting with fluorescein derivatives (DCF-ZZH-0, DCF-ZZH-1 and DCF-ZZH) at 37°C for 12 minutes to detect the change in fluorescence intensity. The test results of the fluorescence intensity at an emission wavelength of 620 nm are shown in Table 1.
[0126] Table 1 Fluorescence intensity response of fluorescein derivatives to various biologically relevant analytes (au)
[0127]
[0128]
[0129] The results showed that the fluorescence intensity was significantly enhanced after the addition of quinone oxidoreductase, while other analytes had little effect on the fluorescence intensity, proving that the fluorescein derivatives (DCF-ZZH-0, DCF-ZZH-1 and DCF-ZZH) have a specific response to quinone oxidoreductase and have little response to other biological analytes.
[0130] 2. Linear Relationship
[0131] The responses of three fluorescein derivatives (DCF-ZZH-0, DCF-ZZH-1 and DCF-ZZH) prepared in Examples 1 to 3 of the present invention to different concentrations of quinone oxidoreductase were studied, and a linear relationship between quinone oxidoreductase concentration and fluorescence intensity was established.
[0132] Using a fluorescence spectrophotometer, the excitation wavelength is 550nm, and the emission wavelength receiving range is 580-660nm. A detection solution with a fluorescein derivative concentration of 10μM, a bovine serum albumin (BSA) mass concentration of 0.007% and a reduced coenzyme II (NADPH) concentration of 100μM was prepared using 10mM PBS (pH=7.4) buffer. Different concentrations of quinone oxidoreductase (0.1-1μg / mL) were added to the detection solution, respectively, and the reaction was carried out at 37℃ for 12min, and the effect on the luminescence intensity of each fluorescein derivative was observed. The test results of the fluorescence intensity at the emission wavelength of 620nm are shown in Table 2.
[0133] Table 2 Fluorescence response intensity of fluorescein derivatives to different concentrations of quinone oxidoreductase (au)
[0134]
[0135] The test results show that the emission intensity of each fluorescein derivative prepared in Examples 1 to 3 has a good linear relationship with the quinone oxidoreductase concentration between 0.1 and 1 μg / mL. Among them, the linear equation of the DCF-ZZH-0 fluorescein derivative prepared in Example 1 is y=7271x+1113(R 2 =0.9858); the linear equation of the DCF-ZZH-1 fluorescein derivative prepared in Example 2 is y=5937x+1641(R 2 =0.9969); the linear equation of the DCF-ZZH fluorescein derivative prepared in Example 3 is y=7637x+986(R 2 =0.9911). The results show that the fluorescein derivatives (DCF-ZZH-0, DCF-ZZH-1 and DCF-ZZH) prepared in the examples of the present invention can achieve accurate quantitative detection of quinone oxidoreductase.
[0136] The detection limits of the fluorescein derivatives prepared in Examples 1-3 for quinone oxidoreductase were calculated according to the above linear equation. The detection limit of the DCF-ZZH-0 fluorescein derivative prepared in Example 1 was 21.27 ng / mL, the detection limit of the DCF-ZZH-1 fluorescein derivative prepared in Example 2 was 24.06 ng / mL, and the detection limit of the DCF-ZZH fluorescein derivative prepared in Example 3 was 18.16 ng / mL.
[0137] 3. Cytotoxicity Assay
[0138] The three fluorescein derivatives (DCF-ZZH-0, DCF-ZZH-1 and DCF-ZZH) prepared in Examples 1 to 3 of the present invention were subjected to cytotoxicity experiments.
[0139] The MTT assay was used to investigate the cytotoxicity of fluorescein derivatives (DCF-ZZH-0, DCF-ZZH-1, and DCF-ZZH) in different cell lines (A549, HUVEC, OVCAR-3, HeLa, MCF-7, HepG2, HL-60, and L-02). Cells in the logarithmic growth phase (8×10 3 cells / well) were seeded in a 96-well plate and incubated at 37°C and 5% CO 2After 24 hours of incubation in the incubator, the culture medium was removed, and different concentrations of fluorescein derivatives (2.5 μM, 10 μM, 20 μM, 40 μM, 80 μM) were co-incubated with each cell for 24 hours, and then 10 μL of MTT reagent (5 mg / mL) and 90 μL of culture medium were added, and the cells were further incubated in the incubator for 4 hours. The culture medium was removed, and 100 μL of dimethyl sulfoxide was added to each well. After shaking, the OD value was measured at 490 nm by an enzyme marker, and the cell survival rate (%) was calculated. The test results are shown in Tables 3-5.
[0140] The cell viability was calculated as follows:
[0141]
[0142] Among them, A549, HUVEC, OVCAR-3, MCF-7, HepG2, HL-60, and L-02 cells were cultured with RPMI-1640 medium, and HeLa cells were cultured with DMEM medium.
[0143] Table 3 Cell survival rate of different concentrations of DCF-ZZH-0 (%)
[0144]
[0145] Table 4 Cell survival rate of different concentrations of DCF-ZZH-1 (%)
[0146]
[0147]
[0148] Table 5 Cell survival rate of different concentrations of DCF-ZZH (%)
[0149]
[0150] The test results show that the survival rate of each cell is above 85%. The MTT experiment shows that the fluorescein derivatives (DCF-ZZH-0, DCF-ZZH-1 and DCF-ZZH) have almost no toxic side effects on the above cells and have good biocompatibility.
[0151] 4. Differentiation between tumor cells and normal cells
[0152] The ability of three fluorescein derivatives (DCF-ZZH-0, DCF-ZZH-1 and DCF-ZZH) prepared in Examples 1 to 3 of the present invention to differentiate tumor cells from normal cells was studied.
[0153] Compared with normal cells, quinone oxidoreductase is overexpressed in tumor cells. Tumor cells (A549, OVCAR-3, MCF-7, HeLa, HepG2) and normal cells (HUVEC, L02) were seeded in six-well plates (2×10 5 cells / well) at 37°C and 5% CO 2 After culturing in the incubator for 24 hours, the culture medium was removed, and then the fluorescein derivatives (DCF-ZZH-0, DCF-ZZH-1 and DCF-ZZH) (10 μM) were added to each six-well plate, and after incubation for 30 minutes, the remaining fluorescein derivatives were washed off with PBS buffer 2-3 times, and then imaged with a fluorescence microscope, with an excitation wavelength of 550 nm and an emission wavelength receiving range of 580-660 nm. Image analysis was processed with Image J software to detect changes in fluorescence intensity, and the results are shown in Table 6.
[0154] Among them, A549, OVCAR-3, MCF-7, HepG2, L-02, and HUVEC cells were cultured with RPMI-1640 medium, and HeLa cells were cultured with DMEM medium.
[0155] Table 6 Fluorescence response of fluorescein derivatives to each cell (au)
[0156]
[0157] The experimental results show that the fluorescence intensity of fluorescein derivatives (DCF-ZZH-0, DCF-ZZH-1 and DCF-ZZH) in tumor cells (A549, OVCAR-3, MCF-7, HeLa, HepG2) is significantly enhanced, which is the result of high expression of quinone oxidoreductase in tumor cells; in sharp contrast, weak fluorescence is shown in normal cells (HUVEC, L02). The results show that fluorescein derivatives (DCF-ZZH-0, DCF-ZZH-1 and DCF-ZZH) have good tumor cell targeting, and can quickly distinguish tumor cells from normal cells and different types of tumor cells through the difference in the expression level of quinone oxidoreductase, and have great potential in early diagnosis of tumors.
[0158] 5. Fluorescence Imaging
[0159] Fluorescence imaging of the fluorescein derivative DCF-ZZH prepared in Example 3 of the present invention in living cells;
[0160] Tumor A549 cells were seeded in six-well plates (2×10 5 cells / well) in RPMI-1640 medium at 37°C and 5% CO 2After culturing in an incubator for 24 hours, the culture medium was removed and the tumor A549 cells were co-incubated with a 10 μM fluorescein derivative DCF-ZZH solution for 5 minutes, 10 minutes, 20 minutes, and 40 minutes, respectively. The remaining fluorescein derivatives were washed off with PBS 2-3 times, and then imaged using a fluorescence microscope with an excitation wavelength of 550 nm and an emission wavelength receiving range of 580-660 nm. The fluorescence imaging results are shown in Figure 2. Figure 1 shown.
[0161] As can be seen from the figure, there is no obvious fluorescence at 5 minutes of co-incubation (a), weak fluorescence appears at 10 minutes of co-incubation (b), fluorescence is significantly enhanced at 20 minutes of co-incubation (c), and strong fluorescence appears at 40 minutes of co-incubation (d). The results show that DCF-ZZH can stain tumor A549 cells in a short time (20 minutes) and has good tumor cell targeting.
[0162] 6. Fluorescence imaging of tumor cells with different quinone oxidoreductase expression levels using fluorescein derivatives
[0163] The fluorescence imaging of tumor cells with different quinone oxidoreductase expression levels was studied using the fluorescein derivative DCF-ZZH prepared in Example 3 of the present invention.
[0164] Tumor OVCAR-3 cells are a cell line with high expression of quinone oxidoreductase (NQO1+), and tumor A549 cells are a cell line with extremely high expression of quinone oxidoreductase (NQO1++). Tumor OVCAR-3 cells and tumor A549 cells were inoculated into six-well plates (2×10 5 cells / well) at 37°C and 5% CO 2 After culturing in an incubator for 24 h, the culture medium was removed and the fluorescein derivative DCF-ZZH (10 μM) was added to each six-well plate. After incubation for 30 min, the remaining fluorescein derivative was washed off with PBS 2-3 times and then imaged with a fluorescence microscope with an excitation wavelength of 550 nm and an emission wavelength receiving range of 580-660 nm.
[0165] Tumor A549 cells were seeded in six-well plates (2×10 5 cells / well) at 37°C and 5% CO 2After 24 hours of culture in the incubator, the culture medium was removed, and dicoumarol (50 μM) was added to the six-well plate for pre-incubation for 20 minutes. Then, the fluorescein derivative DCF-ZZH (10 μM) was added to each six-well plate, and the plates were incubated for 30 minutes. The remaining fluorescein derivatives were washed off with PBS 2-3 times, and then the images were taken with a fluorescence microscope. The excitation wavelength was 550 nm, and the emission wavelength reception range was 580-660 nm. The cell culture medium without dicoumarol was used as the normal group (Normal group). The fluorescence imaging results are shown in Figure 2. Figure 2 shown.
[0166] Among them, A549 and OVCAR-3 cells were cultured in RPMI-1640 medium.
[0167] As can be seen from the figure, ab is the fluorescence imaging of DCF-ZZH on tumor OVCAR-3 cells (NQO1+) and tumor A549 cells (NQO1++), respectively; cd is the fluorescence imaging of the inhibition test of dicoumarol (50μM) in tumor A549 cells. It can be seen that fluorescence can be observed in NQO1+ tumor OVCAR-3 cells (a); the fluorescence intensity of NQO1++ tumor A549 cells is significantly enhanced compared with tumor OVCAR-3 cells (b). Compared with Figure c without dicoumarol, almost no fluorescence was observed after incubating tumor A549 cells with dicoumarol to inhibit the quinone oxidoreductase therein (d). This result further shows that the fluorescence enhancement of the fluorescein derivative DCF-ZZH comes from the quinone oxidoreductase in tumor cells, and its high sensitivity can be applied to tumor cell fluorescence detection to distinguish different types of tumor cells.
[0168] 7. Singlet oxygen ( 1 O 2 )'s ability to generate
[0169] The singlet oxygen ( 1 O 2 ) to conduct a comparative study on the production capacity.
[0170] The product after the action of the fluorescein derivative and the quinone oxidoreductase corresponds to the intermediate product (DCF-LHF-0, DCF-LHF-1 and DCF-LHF) prepared in step (2) of Examples 1 to 3.
[0171] The experiment used commercial photosensitizer protoporphyrin (PpIX), intermediate products (DCF-LHF-0, DCF-LHF-1 and DCF-LHF) and fluorescein derivatives (DCF-ZZH-0, DCF-ZZH-1 and DCF-ZZH) for the experiment. 1 O 2 For the comparison of generation rates, 1,3-diphenylisobenzofuran (DPBF) was selected as 1 O 2 Good indicator, when present 1 O 2 When 1,3-diphenylisobenzofuran (DPBF) is oxidized and consumed, the absorption band of 1,3-diphenylisobenzofuran (DPBF) at 410nm is weakened. Therefore, the generation of fluorescein derivatives can be evaluated by detecting the change in absorption intensity at 410nm. 1 O 2 ability.
[0172] First, protoporphyrin (PpIX), intermediate products, and fluorescein derivatives (10 μM) were dissolved in acetonitrile (30 mL) with 1,3-diphenylisobenzofuran (DPBF, 50 μM) under light-free conditions. After magnetic stirring, the mixture was uniformly irradiated with an LED lamp (wavelength 590 nm, irradiation density 16 mW / cm 2 ) as a light source to illuminate the solution (1 min), stirring was continued during the entire illumination, and the UV-visible absorption spectrum of the sample was measured after completion, and the absorbance value at 410 nm was recorded. A solution without protoporphyrin (PpIX), intermediate product, and fluorescein derivative was used as a blank control group (CTR group). The test results are shown in Table 7.
[0173] Table 7 Fluorescein derivatives 1 O 2 Generation rate (au)
[0174]
[0175] The experimental results show that the pure fluorescein derivatives (DCF-ZZH-0, DCF-ZZH-1 and DCF-ZZH) produce 1 O 2 The ability of DCF-LHF-0, DCF-LHF-1 and DCF-LHF after the reaction with quinone oxidoreductase is weak. 1 O 2 Generate capacity, and 1 O 2 Producing capacity higher than commercialization 1 O 2These results suggest that protoporphyrin (PpIX) can be used as an excellent photosensitizer for photodynamic therapy, with almost no toxic side effects on normal cells and tissues.
[0176] 8. Research on the application of fluorescein derivatives in photodynamic therapy
[0177] The three fluorescein derivatives (DCF-ZZH-0, DCF-ZZH-1, DCF-ZZH) prepared in Examples 1 to 3 were applied to photodynamic therapy to study their photodynamic therapy effects. The commercial photosensitizer protoporphyrin (PpIX) was used to compare the photodynamic therapy effects with each fluorescein derivative (DCF-ZZH-0, DCF-ZZH-1, DCF-ZZH).
[0178] Tumor A549 cells and normal HUVEC cells were seeded in 96-well plates (8×10 3 cells / well) at 37°C and 5% CO 2 The cells were cultured in an incubator for 24 h, the culture medium was removed, protoporphyrin (PpIX) and each fluorescein derivative (10 μM) were added to the 96-well plate, and the cells were incubated for 24 h. Fresh culture medium was replaced and the cells were balanced for 1 h before being illuminated with a 590 nm LED light (16 mW / cm 2 ) irradiated for 20 min, 50 μL MTT reagent (5 mg / mL) was added to each well, and the culture was continued for 4 h. The culture medium was carefully discarded, and dimethyl sulfoxide (100 μL) was added to each well to dissolve the cells. After shaking, the OD value was measured at 490 nm by a microplate reader to calculate the cell survival rate. The cell culture medium without protoporphyrin (PpIX) and each fluorescein derivative was used as a blank group (CTR group). The test results are shown in Table 8.
[0179] Among them, A549 and HUVEC cells were cultured in RPMI-1640 medium.
[0180] The cell viability was calculated as follows:
[0181]
[0182] Table 8 Survival rate of each cell after photodynamic therapy
[0183]
[0184]
[0185] As can be seen from the table, the survival rate of tumor A549 cells was significantly reduced, while the survival rate of normal cells HUVEC was not affected; the cytotoxicity levels of fluorescein derivatives (DCF-ZZH-0, DCF-ZZH-1, DCF-ZZH) and PpIX were almost the same. The results further showed that the fluorescein derivatives DCF-ZZH-0, DCF-ZZH-1 and DCF-ZZH had excellent photodynamic therapy effects and had almost no toxic side effects on normal cells and tissues.
[0186] The fluorescein derivatives 4-8 prepared in the above Examples 4-8 have high sensitivity to quinone oxidoreductase (the minimum detection limit can reach 20-50 ng / mL), and have almost no toxic side effects on normal cells and tissues (MTT cytotoxicity test, the cell survival rate is more than 85%), and can be used as excellent fluorescent probes for qualitative and quantitative detection of quinone oxidoreductase and biological research, tumor cell fluorescence detection, differentiation of different types of tumor cells and tumor targeting. However, fluorescein derivatives 4-5 do not have the effect of being a photosensitizer for photodynamic therapy. Fluorescent derivatives 6-8 can be used as sensitizers for photodynamic therapy (after photodynamic therapy, the cell survival rate of tumor cells in MTT cytotoxicity test is less than 20%), and can be used as excellent fluorescent probes for tumor targeting and photodynamic therapy.
[0187] In summary, the fluorescein derivatives provided by the present invention not only have excellent detection sensitivity and specificity for quinone oxidoreductase, but also have good singlet oxygen generation ability after the product of the reaction with quinone oxidoreductase, and have almost no toxic side effects on normal cells and tissues. Therefore, they can not only be used as excellent fluorescent probes for qualitative and quantitative detection and biological research of quinone reductase, tumor cell fluorescence detection and differentiation of different types of tumor cells, but also can be used as photosensitizers for photodynamic therapy, thereby improving the effect of photodynamic therapy. Their application in the treatment of various tumor diseases can realize integrated diagnosis and treatment, and they have high practical application value.
[0188] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modification, equivalent substitution or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims
1. A fluorescein derivative, characterized in that Its structure is shown in Formula I: Wherein, X and X0 are selected from H, F, Cl, Br or I respectively; R, R1 are 2. The fluorescein derivative according to claim 1, characterized in that Its structural formula is:
3. A fluorescein derivative, characterized in that Its structure is shown in formula III: Wherein, X and X0 are selected from H, F, Cl, Br or I respectively; R, R1 are selected from L3 or L6; R4 is selected from (CH2) n ; n is an integer from 0 to 8.
4. The fluorescein derivative according to claim 3, characterized in that Its structure is as follows:
5. A method for preparing the fluorescein derivative according to any one of claims 1 to 4, characterized in that: The steps include: Step a, dissolving compound 1 and urotropine in an organic solvent a, reacting at 70° C.-160° C. for 20 h-40 h, cooling, adjusting the pH of the reaction solution to 2-4, filtering, washing, and drying to obtain compound 2; Step b, under an inert atmosphere, dissolving compound 2 in an organic solvent b, adding intermediate a and piperidine, reacting at 90° C.-180° C. for 30 h-40 h, cooling, and purifying to obtain compound 3; Wherein, the intermediate a is selected from the following compounds: Step c, under an inert atmosphere, compound 4, intermediate Q, 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate and N,N-diisopropylethylamine are added to an organic solvent c, reacted at 0°C-5°C for 5min-30min, heated to 10°C-30°C for 18h-60h, cooled, and purified to obtain compound 5; Among them, intermediate Q is NH2(C6H4)R4COOH, and compound 5 is: R4 is selected from (CH2) n ; n is an integer from 0 to 8; Step d, under an inert atmosphere, compound 3, compound 4, 4-dimethylaminopyridine and dicyclohexylcarbodiimide are added to an organic solvent d, reacted at 0°C-5°C for 0.1h-2.5h, heated to 50°C-150°C for 1h-3.5h, cooled to 10°C-30°C, and continued to react for 18h-48h to obtain a fluorescein derivative represented by formula I; Under an inert atmosphere, compound 3, compound 5, 4-dimethylaminopyridine and dicyclohexylcarbodiimide are added to an organic solvent d, reacted at 0°C-5°C for 0.1h-2.5h, heated to 50°C-150°C for 1h-3.5h, cooled to 10°C-30°C, and continued to react for 18h-48h to obtain a fluorescein derivative represented by formula III.
6. The method for preparing a fluorescein derivative according to claim 5, characterized in that: In step a, the molar ratio of compound 1 to urotropine is 1:(2-6); and / or In step a, the molar ratio of compound 1 to organic solvent a is 1:(50-300); and / or In step a, the organic solvent a is at least one of trifluoroacetic acid, dichloromethane, chloroform, ethanol, acetonitrile, ethyl acetate, toluene, xylene or o-dichlorobenzene.
7. The method for preparing a fluorescein derivative according to claim 5, characterized in that: In step b, the molar ratio of compound 2 to intermediate a is 1:(1-8); and / or In step b, the molar ratio of compound 2 to piperidine is 1:(2-8); and / or In step b, the molar ratio of compound 2 to organic solvent b is 1:(100-600); and / or In step b, the organic solvent b is at least one of methanol, ethanol, acetonitrile, toluene, xylene, o-dichlorobenzene or N,N-dimethylformamide.
8. The method for preparing a fluorescein derivative according to claim 5, characterized in that: In step c, the molar ratio of compound 4, intermediate Q, 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate and N,N-diisopropylethylamine is 1:(1-2):(1-6):(15-30); and / or In step c, the molar ratio of compound 4 to organic solvent c is 1:(300-1500); In step c, the organic solvent c is at least one of dichloromethane, acetonitrile, toluene, xylene, o-dichlorobenzene or N,N-dimethylformamide.
9. The method for preparing a fluorescein derivative according to claim 5, characterized in that: In step d, the molar ratio of compound 3, compound 4, 4-dimethylaminopyridine and dicyclohexylcarbodiimide is 1:(10-25):(1-8):(20-30); and / or In step d, the molar ratio of compound 3, compound 5, 4-dimethylaminopyridine and dicyclohexylcarbodiimide is 1:(15-30):(1-12):(20-30); and / or In step d, the molar ratio of compound 3 to organic solvent d is 1:(1000-2500); and / or In step d, the organic solvent d is at least one of dichloromethane, acetonitrile, toluene, xylene, o-dichlorobenzene or N,N-dimethylformamide.
10. A fluorescent probe, characterized in that The invention comprises the fluorescein derivative according to any one of claims 1 to 4.
Citation Information
Patent Citations
Cleavable Nucleotide Analogs and Uses Thereof
US20200080122A1
Quinone-masked probes as labeling reagents for cell uptake measurements
WO2015116867A1
